Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer
- PMID: 20698116
Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer
Abstract
The aim of this research was to determine the VEGF A expression in tumor cells and the intratumoral microvessel density and their prognostic significance in the survival of the subjects. 87 subjects were monitored retrospectively for a period of 60 to 132 months. The subjects were treated at the Department of Obstetrics and Gynecology of Osijek University Hospital Center, Croatia. We analysed standard clinical, pathohistological and therapeutical prognostic factors, intratumoral microvessel density and expression of VEGF A. Five-year survival was calculated by the life chart method and presented graphically by Kaplan-Meier curves. Reaching conclusions on statistical hypotheses in this paper was done with a reliability level p < 0.05. Of the analyzed clinical prognostic factors, those which proved to be statistically significant and independent prognostic factors were age and clinical stage of the disease, and of pathohistologic ones it was the depth of myometrial invasion and VEGF expression. An elevated VEGF expression is associated with deep myometrial invasion, poorly differentiated tumors, histologic type and intratumoral microvessel density to a statistically significant degree. Elevated VEGF expression, age, FIGO stage and depth of myometrial invasion play a significant prognostic role in patients with endometrial cancer. VEGF receptors could be a target for adjuvant therapy in VEGF positive endometrial cancer.
Similar articles
-
VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.Gynecol Oncol. 2000 Jan;76(1):33-9. doi: 10.1006/gyno.1999.5658. Gynecol Oncol. 2000. PMID: 10620438
-
Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.Acta Obstet Gynecol Scand. 1999 Sep;78(8):728-34. Acta Obstet Gynecol Scand. 1999. PMID: 10468067
-
Angiostatin expression in endometrial cancer.Oncol Rep. 2002 Nov-Dec;9(6):1193-6. Oncol Rep. 2002. PMID: 12375018
-
[Angiogenesis-prognostic factor in patients with endometrial cancer].Ginekol Pol. 2005 Oct;76(10):838-45. Ginekol Pol. 2005. PMID: 16417101 Review. Polish.
-
[Molecular prognostic factors and pathogenesis of endometrial cancer].Ceska Gynekol. 2006 Jul;71(4):355-60. Ceska Gynekol. 2006. PMID: 16956055 Review. Czech.
Cited by
-
VEGF Immunoexpression in Endometrioid Endometrial Carcinomas.Curr Health Sci J. 2022 Apr-Jun;48(2):155-161. doi: 10.12865/CHSJ.48.02.03. Epub 2022 Jun 30. Curr Health Sci J. 2022. PMID: 36320870 Free PMC article.
-
Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models.Oncol Lett. 2012 Nov;4(5):976-980. doi: 10.3892/ol.2012.856. Epub 2012 Aug 8. Oncol Lett. 2012. PMID: 23162635 Free PMC article.
-
Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer.Biomolecules. 2021 Dec 21;12(1):7. doi: 10.3390/biom12010007. Biomolecules. 2021. PMID: 35053155 Free PMC article. Review.
-
The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer.Onco Targets Ther. 2017 Sep 19;10:4617-4624. doi: 10.2147/OTT.S132558. eCollection 2017. Onco Targets Ther. 2017. PMID: 29033580 Free PMC article. Review.
-
Expression of Vascular Endothelial Growth Factor-A (VEGF-A) in Adenocarcinoma and Squamous Cell Cervical Cancer and Its Impact on Disease Progression: Single Institution Experience.Medicina (Kaunas). 2023 Jun 23;59(7):1189. doi: 10.3390/medicina59071189. Medicina (Kaunas). 2023. PMID: 37512001 Free PMC article.